Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Announces Earnings Results, Beats Estimates By $0.04 EPS

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) issued its quarterly earnings results on Monday, August 3rd. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.62 by $0.04, Zacks reports. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.83% and a return on equity of 9.28%. The firm had revenue of $5.55 billion for the quarter, compared to analysts’ expectations of $5.48 billion.

Fresenius Medical Care AG & Co. KGaA Price Performance

Shares of Fresenius Medical Care AG & Co. KGaA stock traded down $0.25 during trading on Friday, hitting $23.02. 446,230 shares of the company’s stock traded hands, compared to its average volume of 689,239. The company has a market cap of $12.36 billion, a PE ratio of 11.93, a PEG ratio of 4.34 and a beta of 0.77. The firm’s fifty day moving average price is $23.95 and its 200 day moving average price is $23.12. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $20.02 and a twelve month high of $27.64. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.07 and a quick ratio of 0.75.

Analyst Ratings Changes

Several analysts have issued reports on FMS shares. Weiss Ratings restated a “hold (c)” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 4th. Citigroup reissued a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, July 17th. Zacks Research raised Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Wall Street Zen lowered Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Jefferies Financial Group raised shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a research report on Friday, May 8th. Six investment analysts have rated the stock with a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat, Fresenius Medical Care AG & Co. KGaA currently has a consensus rating of “Reduce” and an average price target of $23.57.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of institutional investors have recently added to or reduced their stakes in the stock. Morgan Stanley grew its position in Fresenius Medical Care AG & Co. KGaA by 47.2% in the fourth quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock valued at $70,027,000 after acquiring an additional 942,497 shares during the period. Bank of America Corp DE lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 279.7% during the second quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock valued at $9,637,000 after acquiring an additional 248,477 shares during the period. Integral Health Asset Management LLC boosted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 44.4% in the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock valued at $15,483,000 after purchasing an additional 200,000 shares in the last quarter. Qube Research & Technologies Ltd grew its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 175.3% in the 2nd quarter. Qube Research & Technologies Ltd now owns 199,563 shares of the company’s stock worth $5,702,000 after purchasing an additional 127,073 shares during the last quarter. Finally, XTX Topco Ltd increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 743.3% during the 4th quarter. XTX Topco Ltd now owns 94,093 shares of the company’s stock worth $2,241,000 after purchasing an additional 82,935 shares in the last quarter. 8.37% of the stock is owned by institutional investors and hedge funds.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.